Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Glioblastoma 5Triple Negative Breast Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Colorectal Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1

Interventions

enzalutamide 4Abiraterone Acetate 2radium Ra 223 dichloride 1dactolisib 1abiraterone 1VT-464 1Prednisone 1NVP-BKM120 1Flutamide 1Crizotinib 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castration-resistant Prostate Cancer × NVP-BKM120 × Clear all
NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡